Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A
4(100.0%)
4Total
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06038513Not ApplicableTerminated

Transnasal Induction of Normothermia for Neurogenic Fever

Role: lead

NCT06051604Not ApplicableCompleted

Mi-Helper Transnasal Cooling for Acute Treatment of Migraine

Role: lead

NCT04936061Not ApplicableTerminated

Transnasal Cooling for Migraine

Role: lead

NCT03360656Not ApplicableCompleted

Transnasal Induction of Normothermia in Febrile Stroke Patients

Role: lead

All 4 trials loaded